<h4>Background</h4>Real-world evidence regarding the use of dacomitinib as a first-line therapy for advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This evidence concerns the gene EGFR and non-small cell lung carcinoma.